NR 566 Midterm Exam
Chamberlain Questions and Ansẉers with
rationales 2026\2027 update
This Exam contains:
Guarantee passing score
Questions and Ansẉers
format set of multiple-choice
Expert-Verified rationales
Verified ẉith trusted textbooks
,───────────────────────────────────────────────────────
─
1. Which of the following describes the process by which a drug is
converted from a lipophilic to a hydrophilic molecule to facilitate
renal excretion?
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
Answer: C
Rationale: Metabolism (primarily hepatic) converts lipophilic drugs
into hydrophilic metabolites so they can be easily excreted by the
kidneys.
2. A patient with severe liver cirrhosis has decreased levels of
albumin. How will this affect the pharmacokinetics of highly protein-
bound drugs like warfarin?
A) Increased free drug levels, leading to potential toxicity
B) Decreased free drug levels, leading to therapeutic failure
C) Increased metabolism of the drug
D) Enhanced renal excretion of the drug
Answer: A
Rationale: With less albumin available to bind the drug, more free
(active) drug circulates in the plasma, increasing the risk of toxicity.
3. Which cytochrome P450 enzyme is responsible for metabolizing
the majority of clinically prescribed drugs and is the most common
site for drug-drug interactions?
A) CYP2D6
B) CYP3A4
C) CYP1A2
D) CYP2C9
,Answer: B
Rationale: CYP3A4 metabolizes approximately 50% of all clinically
used drugs and is highly susceptible to inhibition or induction.
4. A patient is taking a medication that is a CYP3A4 inhibitor. If they
are prescribed a new drug metabolized by CYP3A4, the provider
should expect:
A) Decreased levels of the new drug
B) Increased levels of the new drug
C) No change in drug levels
D) Immediate anaphylaxis
Answer: B
Rationale: Inhibiting the enzyme slows the metabolism of the new
drug, causing its plasma levels to rise, potentially leading to
toxicity.
5. The term "bioavailability" refers to:
A) The rate at which a drug is excreted
B) The fraction of an administered dose of unchanged drug that
reaches the systemic circulation
C) The ability of a drug to bind to a receptor
B) The volume of distribution of a drug
Answer: B
Rationale: Bioavailability is the percentage of the administered dose
that reaches the systemic circulation. For IV drugs, it is 100%.
6. A drug with a narrow therapeutic index (NTI) requires monitoring
because:
A) It is highly protein-bound
B) The toxic dose is very close to the therapeutic dose
C) It undergoes extensive first-pass metabolism
D) It is excreted entirely unchanged by the kidneys
Answer: B
, Rationale: NTI drugs (like digoxin or warfarin) have a small margin
between therapeutic efficacy and toxicity, requiring serum drug
monitoring.
7. A drug that binds to a receptor and produces a maximal response
is classified as a:
A) Partial agonist
B) Antagonist
C) Full agonist
D) Inverse agonist
Answer: C
Rationale: A full agonist has high efficacy, binding to the receptor
and producing the maximum possible response.
8. Which of the following is an example of a pharmacodynamic drug
interaction?
A) Ketoconazole inhibiting the metabolism of cyclosporine
B) Warfarin and aspirin both inhibiting clotting mechanisms,
increasing bleeding risk
C) Aluminum antacids blocking the absorption of ciprofloxacin
D) Probenecid decreasing the renal tubular secretion of penicillin
Answer: B
Rationale: Pharmacodynamic interactions occur when two drugs
have additive, synergistic, or antagonistic effects at the same
receptor or physiological system.
9. Phase II metabolic reactions typically involve:
A) Oxidation
B) Reduction
C) Hydrolysis
D) Conjugation
Answer: D
Chamberlain Questions and Ansẉers with
rationales 2026\2027 update
This Exam contains:
Guarantee passing score
Questions and Ansẉers
format set of multiple-choice
Expert-Verified rationales
Verified ẉith trusted textbooks
,───────────────────────────────────────────────────────
─
1. Which of the following describes the process by which a drug is
converted from a lipophilic to a hydrophilic molecule to facilitate
renal excretion?
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
Answer: C
Rationale: Metabolism (primarily hepatic) converts lipophilic drugs
into hydrophilic metabolites so they can be easily excreted by the
kidneys.
2. A patient with severe liver cirrhosis has decreased levels of
albumin. How will this affect the pharmacokinetics of highly protein-
bound drugs like warfarin?
A) Increased free drug levels, leading to potential toxicity
B) Decreased free drug levels, leading to therapeutic failure
C) Increased metabolism of the drug
D) Enhanced renal excretion of the drug
Answer: A
Rationale: With less albumin available to bind the drug, more free
(active) drug circulates in the plasma, increasing the risk of toxicity.
3. Which cytochrome P450 enzyme is responsible for metabolizing
the majority of clinically prescribed drugs and is the most common
site for drug-drug interactions?
A) CYP2D6
B) CYP3A4
C) CYP1A2
D) CYP2C9
,Answer: B
Rationale: CYP3A4 metabolizes approximately 50% of all clinically
used drugs and is highly susceptible to inhibition or induction.
4. A patient is taking a medication that is a CYP3A4 inhibitor. If they
are prescribed a new drug metabolized by CYP3A4, the provider
should expect:
A) Decreased levels of the new drug
B) Increased levels of the new drug
C) No change in drug levels
D) Immediate anaphylaxis
Answer: B
Rationale: Inhibiting the enzyme slows the metabolism of the new
drug, causing its plasma levels to rise, potentially leading to
toxicity.
5. The term "bioavailability" refers to:
A) The rate at which a drug is excreted
B) The fraction of an administered dose of unchanged drug that
reaches the systemic circulation
C) The ability of a drug to bind to a receptor
B) The volume of distribution of a drug
Answer: B
Rationale: Bioavailability is the percentage of the administered dose
that reaches the systemic circulation. For IV drugs, it is 100%.
6. A drug with a narrow therapeutic index (NTI) requires monitoring
because:
A) It is highly protein-bound
B) The toxic dose is very close to the therapeutic dose
C) It undergoes extensive first-pass metabolism
D) It is excreted entirely unchanged by the kidneys
Answer: B
, Rationale: NTI drugs (like digoxin or warfarin) have a small margin
between therapeutic efficacy and toxicity, requiring serum drug
monitoring.
7. A drug that binds to a receptor and produces a maximal response
is classified as a:
A) Partial agonist
B) Antagonist
C) Full agonist
D) Inverse agonist
Answer: C
Rationale: A full agonist has high efficacy, binding to the receptor
and producing the maximum possible response.
8. Which of the following is an example of a pharmacodynamic drug
interaction?
A) Ketoconazole inhibiting the metabolism of cyclosporine
B) Warfarin and aspirin both inhibiting clotting mechanisms,
increasing bleeding risk
C) Aluminum antacids blocking the absorption of ciprofloxacin
D) Probenecid decreasing the renal tubular secretion of penicillin
Answer: B
Rationale: Pharmacodynamic interactions occur when two drugs
have additive, synergistic, or antagonistic effects at the same
receptor or physiological system.
9. Phase II metabolic reactions typically involve:
A) Oxidation
B) Reduction
C) Hydrolysis
D) Conjugation
Answer: D
